Finally, we combined the APE-adjuvant vaccine with anti-programmed cell death 1 ligand 1 antibody (anti-PD-1) to further amplify the effector T cell potency and induce potent anti-tumor immune responses. Here, PDCD1 is linked to neoplasm.